Living Cell Technologies Limited (ASX:LCT)


right-arrow Created with Sketch. 0 (0%)
MCAP $5.141M
Last trade 09.17am 27/01/2022 20mins delayed

Latest Announcements

24/01/2022 Price SensitivePSLCTLiving Cell Technologies Limited
29/12/2021LCTLiving Cell Technologies Limited
29/12/2021LCTLiving Cell Technologies Limited
29/12/2021 Price SensitivePSLCTLiving Cell Technologies Limited
21/12/2021LCTLiving Cell Technologies Limited
15/12/2021LCTLiving Cell Technologies Limited
14/12/2021LCTLiving Cell Technologies Limited
13/12/2021LCTLiving Cell Technologies Limited

Company Overview

Living Cell Technologies Limited (LCT) is an Australia-based biotechnology company. The Company is focused on discovering and developing treatments for conditions, such as Parkinson's disease, diabetes, obesity and migraine. The Company's product pipeline consists of LP-003 for anti-obesity, LC-002 for migraine treatment and NTCELL for Parkinson's disease. Its Long-acting Pramlintide, LP-003 is a peptide drug that reduces caloric intake targeting obesity and it is also used for the treatment of diabetes. LC-002, is a receptor blocker targeting calcitonin gene-related peptide (CGRP), a neuropeptide hormone found in the nervous system. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson's disease. NTCELL's choroid plexus cells are coated with LCT's IMMUPEL technology to protect them from attack by the immune system. It has completed Phase I/IIa clinical trial and phase IIb trials for mid- to late-stage Parkinson's disease.

LCT in the news

Living Cell Technologies (LCT) receives valid applications for new shares and new…
Living Cell Technologies (LCT) secures funding for its third clinical trial of…
Living Cell Technologies’ (LCT) CEO retires and its Chair Professor Bernie Tuch…
Living Cell Technologies’ (LCT) CEO, Dr Ken Taylor, has revealed that he…

Search Previous Announcements